CRES 203
Alternative Names: CRES-202; CRES-203Latest Information Update: 06 May 2024
At a glance
- Originator Cresence
- Developer biOasis Technologies; Cresence
- Class Antidementias; Neuropeptides
- Mechanism of Action Myelin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 20 Jun 2023 Discontinued for Alzheimer's disease in Norway (unspecified route) before June 2023
- 17 Oct 2022 Early research in Alzheimer's disease in Norway (unspecified route) (Cresence pipeline, October 2022)
- 20 Jun 2022 biOasis Technologies acquires assests related to epidermal growth factor (EGF) from Cresence